Although this model may not fully recapitulate leukemias that develop in patients, particularly under immune surveillance, it can improve understanding of the pathogenesis of KMT2A-AFF1 BCP-ALL and facilitate the development of novel therapeutic and diagnostic approaches. This evidence concerns the gene AFF1 and leukemia.